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Abstract 
The three nicotinamide mononucleotide adenylyltransferase (NMNAT) family members 
synthesize the electron carrier nicotinamide adenine dinucleotide (NAD+) and are essential for 
cellular metabolism. In mammalian axons, NMNAT activity appears to be required for axon 
survival and is predominantly provided by NMNAT2. NMNAT2 has recently been shown to also 
function as a chaperone to aid in the refolding of misfolded proteins. Nmnat2 deficiency in 
mice, or in its ortholog dNmnat in Drosophila, results in axon outgrowth and survival defects. 
Peripheral nerve axons in NMNAT2-deficient mice fail to extend and innervate targets, and 
skeletal muscle is severely underdeveloped. In addition, removing NMNAT2 from established 
axons initiates axon death by Wallerian degeneration. We report here on two stillborn siblings 
with fetal akinesia deformation sequence (FADS), severely reduced skeletal muscle mass and 
hydrops fetalis. Clinical exome sequencing identified compound heterozygous NMNAT2 
variant alleles in both cases. Both protein variants are incapable of supporting axon survival in 
mouse primary neuron cultures when overexpressed. In vitro assays demonstrate altered 
protein stability and/or defects in NAD+ synthesis and chaperone functions. Thus, both patient 
NMNAT2 alleles are null or severely hypo-morphic. These data indicate a previously unknown 
role for NMNAT2 in human neurological development and provide the first direct molecular 
















Nicotinamide Mononucleotide Adenylyltransferase 2 (NMNAT2) both synthesizes the electron 
carrier Nicotinamide Adenine Dinucleotide (NAD+) and acts a protein chaperone. NMNAT2 has 
emerged as a major neuron survival factor. Overexpression of NMNAT2 protects neurons from 
Wallerian degeneration after injury and declining levels of NMNAT2 have been implicated in 
neurodegeneration.  While the role of NMANT2 in neurodegeneration has been extensively 
studied, the role of NMNAT2 in human development remains unclear. In this work, we present 
the first human variants in NMNAT2 identified in two fetuses with severe skeletal muscle 
hypoplasia and fetal akinesia. Functional studies in vitro showed that the mutations impair both 
NMNAT2 NAD+ synthase and chaperone functions. This work identifies the critical role of 






Fetal Akinesia Deformation Sequence (FADS) defines a broad range of disorders unified by 
absent fetal movement resulting in secondary defects often leading to sti llbirth or limited 
postnatal survival 1; 2. These secondary features include edema, hydrops fetalis, craniofacial 
anomalies including micrognathia, lung hypoplasia, rocker bottom feet, intrauterine growth 
restriction, and decreased muscle mass 3. Through previous experimental models of fetal 
paralysis, the secondary findings have been shown to be primari ly caused by a lack of fetal 
movement 1; 4.  FADS has both genetic and environmental causes that can affect any aspect of 














(PNS), neuromuscular junction (NMJ), and/or skeletal muscle. Although most cases of FADS 
do not have a genetic diagnosis, multiple monogenic causes of FADS affecting PNS 
innervation development have been identified to date including RAPSN, DOK7, MUSK 5-7.     
 
Through whole exome sequencing and subsequent Sanger sequencing of a family with two 
fetuses with FADS, we identified compound heterozygous mutations in a gene previously 
unlinked to FADS, nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2). NMNAT 
family members were first shown to play  a role in axon degeneration with the discovery of the 
slow Wallerian Degeneration (WldS) mutant mouse that showed delayed axon degeneration 
post transection 8. The WldS phenotype arose as the result of a spontaneous genomic 
rearrangement generating a fusion protein of NMNAT1 and the N-terminus of UBE4B, an E4 
type ubiquitin ligase9; 10.  Normally NMNAT1 is located only in the nucleus but the partial 
axonal location of the fusion protein leads to a gain-of-function explaining the slow Wallerian 
degeneration phenotype 11. 
There are three canonical NMNAT isoforms and each displays unique subcellular localization 
and tissue specific expression. NMNAT1 is nuclear and broadly expressed, NMNAT2 is in the 
cytoplasm and axoplasm and enriched in the brain. NMNAT3 is proposed to be localized to the 
mitochondria and has lower expression in the brain 12; 13. The functions of all three have been 
studied in mice but until now only NMNAT1 has been linked to human disease. NMNAT1 
mutations cause Leber’s Congenital Amaurosis 9 (LCA9) characterized by photoreceptor-
neuron degeneration resulting in congenital blindness 14-17. Two N-ethyl-N-nitrosourea 
generated Nmnat1 missense mouse mutants develop photoreceptor degeneration and closely 














nervous system phenotype and instead develop splenomegaly and hemolytic anemia 19. 
Hikosaka, et. al. showed NMNAT3 is the predominant NAD producer in the cytoplasm of 
mature erythrocytes and loss of Nmnat3 resulted in defective glycolysis in these cells  19. To 
date, no patients with mutations in NMNAT3 have been identified. These data illuminate the 
tissue specific requirements for NMNAT family members during development. 
An essential role for NMNAT2 in axon growth and survival was established first by RNAi in 
primary neuronal culture and subsequently in MNMAT2-deficient mice 20-22. Acute removal of 
NMNAT2 in vitro from established axons causes axon degeneration through the Wallerian 
pathway, while its constitutive deletion in mice causes defects in PNS and CNS axon 
outgrowth, and consequent underdevelopment of the skeletal muscle which lacks innervation 
21; 22. Other features shared with FADS include craniofacial defects and perinatal lethality due 
to a failure to inflate the lungs at birth 21; 22. Furthermore, RNAi of the Drosophila ortholog 
dNMNAT is also sufficient to trigger spontaneous degeneration of established axons and 
genetic mutation causes growth and survival defects in axons and their presynaptic termini  23-
25. Conversely, overexpression of NMNATs after peripheral nerve transection can delay 
Wallerian degeneration  and rescues all mouse NMNAT2 and Drosophila dNMNAT genetic 
knockdown or deletion phenotypes mentioned above 13.  Deletion of another Wallerian 
pathway gene, Sarm1, also rescues axonal phenotypes in MNMAT2-deficient mice preventing 
perinatal lethality and allowing survival into old age with no overt behavioral changes 26; 27. 
These data demonstrate NMNAT2 protects against an active Wallerian Degeneration pathway 
mediated by SARM1.  Recently, it has been discovered that NMNATs including NMNAT2 act 
as chaperones for protein refolding as well as NAD-synthesizing enzymes 24; 28; 29. NMNAT2 














chaperone function of NMNAT2 has been shown to protect against neurodegeneration in a 
variety of tauopathy models 29; 30. While it remains controversial which function(s) of NMNAT2 
are neuroprotective, we sought to investigate both functions in our patient variants of 
NMNAT2.  Interestingly, we found both functions are impaired. This finding and the striking 




MATERIALS AND METHODS 
Subjects  
Initial exome analysis was performed as a clinical service (Ambry Genetics). Informed consent 
to study the sequence data on a research basis was obtained according to Cincinnati 
Children’s Hospital Medical Center (CCHMC) institutional review board protocol # 2014 -
3789.   Following consent, residual DNA samples were obtained for Sanger sequencing 
confirmation of exome sequencing analysis.  
 
Sanger Sequencing 
Sanger sequencing to confirm the results of whole exome sequencing was performed by PCR 
amplification of exon 5 of NMNAT2 with F primer 5’- gaggttcaggagcgatgaaa-3’ and R primer 5’- 
caggagaagagtgcacacca-3’ using genomic DNA. Exon 9 of NMNAT2 was PCR amplified from 
genomic DNA with F primer 5’- gctcaaatgtgcttgctgaa-3’ and R primer 5’- cagacatgggatggttgatg-
3’. Conservation and protein prediction scores for NMNAT2 R232Q variant were generated by 














generated from existing literature and functional domains annotated by UniProt by homology. 
The crystal structure of NMNAT1 (PDB ID: 1kku) in stereo ribbon view was generated by 
PyMOL (v2.2.3)31.  
 
Histology 
Histology was performed on formalin-fixed, paraffin-embedded patient tissue collected at the 
time of autopsy. Hematoxylin and eosin staining was performed according to standard 
methods at the CCHMC Pathology Core Lab and analyzed by attending pathology physicians.  
 
Constructs  
The R232Q and Q135Pfs*44 NMNAT2 mutations were introduced separately by QuikChangeII 
site-directed mutagenesis (Stratagene) into the complete open reading frame of the canonical 
307 amino acid human NMNAT2 isoform cloned into expression vector pCMV-Tag2 
(Stratagene). The expressed NMNAT2 proteins have a Flag tag and short linker sequence (17 
amino acids) at their N-terminus. The presence of the mutations and absence of other PCR 
errors was confirmed by sequencing (Cogenics). pDsRed2-N1 (Clontech) was used for 
expression of variant Discosoma red fluorescent protein (DsRed) to label micro-injected 
neurons / neurites. pEGFP-C1 (Clontech) was used for expression of enhanced green 
fluorescent protein (GFP) to act as a transfection control and reference for NMNAT2 turnover 
in HEK 293T cells. 
 
HEK 293T transfection and stability assays. HEK 293T cells were cultured in DMEM with 














and 1% penicillin/streptomycin (both Invitrogen), and 10% fetal bovine serum. Cells were 
plated in 24-well format to  reach 50-60% confluence for transfection with Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s instructions. In standard turnover 
experiments (Fig. 4A) 500 ng Flag-NMNAT2 expression construct (wild-type or mutant), 200 
ng of an empty pCMV-Tag series vector, and 100 ng pEGFP were transfected per well. To 
boost expression of the NMNAT2Q135Pfs*44 mutant 700 ng Flag-NMNAT2 expression construct 
and 100 ng pEGFP-C1 were transfected per well (Fig. 4C). After treatment ±10 µM emetine 
hydrochloride (Sigma-Aldrich), cells from single wells were lysed directly in 100 µl 2x Laemmli 
sample buffer and heated to 100C for 5 mins. Equal amounts of extract (either 10 or 15 µl) 
were resolved on 12% SDS polyacrylamide gels, transferred to Immobilon-P membrane 
(Millipore) and probed with antibodies essentially as described previously 20. The following 
primary antibodies were used: mouse monoclonal anti-FLAG M2 (1:2,000 Sigma-Aldrich 
F3165), mouse monoclonal anti-GFP clones 7.1 and 13.1 (1:2,000, Sigma-Aldrich 
11814460001) and rabbit polyclonal -Tubulin (1:7,500, Thermo Fisher Scientific PA5-29444). 
Appropriate HRP-conjugated secondary antibodies were used for band detection with 
SuperSignal™ West Dura Extended Duration Substrate (Thermo Fisher Scientific) using an 
Alliance chemiluminescence imaging system (UVITEC Cambridge).  Relative band intensities 
on captured digital images were determined (area under histogram peaks) using Fiji software 
(http://fiji.sc) 32. 
 
Microinjections and imaging. The preparation of dissociated SCG neuron cultures from wild-
type P0-P2 pups, microinjections, Flag immunostaining and quantification of neurite survival 














concentrations used in each specific injection experiment are described in the Figure 3 legend. 
Fluorescence images were acquired with a Leica DFC365FX fluorescence monochrome 
camera attached to a Leica DMi8 inverted fluorescence microscope (10x objective). Mean 
intensities of Flag immunostaining and DsRed fluorescence signals in injected SCG neurons 
were determined using Fiji software (http://fiji.sc) by thresholding (20, dark background) 
followed by particle analysis (size >250 pixels for 1392x1040 images) to identify neurons with 
signal intensity above background (the threshold value was subtracted from the mean intensity 
values obtained) 32. 
 
NMNAT recombinant protein expression and purification.  
For biochemistry assays (Fig. 5A-G), pET28c plasmid constructs were generated for 
NMNAT2R232Q and NMNAT2Q135Pfs*44 pET28c to produce recombinant proteins with an N-
terminal His tag and linker (MGSSHHHHHHSSGLVPRGSH) for affinity purification that 
matched a previously generated NMNAT2WT construct 33. Expression was carried out in E. coli 
BL21(D3) cells (Invitrogen) following 0.5 mM IPTG induction for 4 h at 25°C with subsequent 
purification using TALON chromatography (Clontech) as described 34. The purified proteins 
were desalted on PD-10 columns (GE Healthcare) in 50 mM HEPES/NaOH buffer, pH 7.5, 1 
mM Tris(2-carboxyethyl)phosphine (TCEP), 20 % glycerol, and stored at -80 °C. Their amount 
was measured by the Bio-Rad protein assay. Their purity was evaluated on SDS 
polyacrylamide gels either after Coomassie staining or immunoblotting. Proteins were 
transferred from gels to Immobilon-P membrane (Millipore) and probed with antibodies as 
described 20. Monoclonal anti-NMNAT2 (1:1,000 Abcam AB5698) or anti-tetra His (0.1 g/ml 














secondary antibodies. SuperSignal™ West Dura Extended Duration Substrate (Thermo Fisher 
Scientific) was used for detection on an Alliance chemiluminescence imaging system (UV ITEC 
Cambridge). 
 
NMNAT enzymatic activity assay.  
Routine assays were done by a spectrophotometric coupled method as described, in 0.5 mL 
mixtures containing 30 mM HEPES/NaOH buffer, pH 7.5, 0.5 mg/mL bovine serum albumin 
(BSA Sigma-Aldrich A7906), 75 mM ethanol, 30 mM semicarbazide (Sigma-Aldrich S2201), 
12.5 U/mL alcohol dehydrogenase (ADH Sigma-Aldrich A7011) 35. NMNAT2WT was assayed at 
25 mM MgCl2 and 1 mM of both ATP and NMN (Fig. 5C). The mutant R232Q was assayed at 
5 mM MgCl2, 5 mM Mg-ATP, and 1 mM NMN (Fig. 5D). For Mg
2+-dependence studies the 
MgCl2 was increased up to 100 mM. Temperature studies were carried out under various 
treatments as indicated (Fig. 5E-G) using apo-enzyme solutions in buffer. With assays at 52 
°C, the reaction mixture at the end of incubation was cooled down to 37 °C and then enzyme 
was re-added to check for activity recovery, thus ruling out heat inactivation of the anci llary 
enzyme ADH. The Km and Kcat values were calculated at 37 °C as described using 0.5-5 mM 
Mg-ATP and 0.05-1 mM NMN for the mutant R232Q, or 0.05-0.6 mM ATP and 0.01-0.15 mM 
NMN for the wild type 36. Due to the known instability of NMNAT2 preparations after thawing, 
enzyme was always added as the last component to start the reaction, and control assays 
were performed in parallel 34. One Unit (U) of NMNAT activity refers to the amount of enzyme 















Gel filtration. Gel filtration of pure NMNAT2R232Q was carried out by FPLC with a Superose 12 
HR 10/30 column (Amersham Pharmacia), equilibrated with 50 mM HEPES/NaOH buffer, pH 
7.5, 0.15 M NaCl, 1 mM DTT. Bovine serum albumin, ovalbumin, and carbonic anhydrase 
were used as the standards. 
 
In-cell luciferase refolding assay. 
HEK 293T cells were cultured in six-well plates and double transfected using jetPRIME 
transfection reagent (VWR International, Radnor, PA, USA) with pCMV-luciferase, and one of 
the following plasmids: pDsRed2 vector (control), pCMV-Hsp70, pCMV-Nmnat3, pCMV-
Nmnat2WT, pCMV-NMNAT2R232Q, and pCMV-NMNAT2Q135Pfs*44. At 48 hrs after transfection, 
protein synthesis was inhibited by adding 1 μg/ml cycloheximide. Cells were subjected to heat 
shock at 42 °C for 45 mins, and then recovered at 37 °C for 3 hours 37. Cells were lysed in 
lysis buffer containing 100 mM KCl, 20 mM HEPES, 5% glycerol, 0.1% Triton X-100, and 1mM 
dithiothreitol. Luciferase activity was measured with the Luciferase Assay System (Promega, 
Madison, WI, USA). 
 
Statistics. Statistical testing of data was performed using Excel (Microsoft) or Prism 



















Clinical Summary of two fetuses with FADS 
Fetus 1. Fetus 1 was born to a 32yo Caucasian female evaluated for non-immune hydrops 
fetalis identified at 21 weeks gestation by ultrasonography.  Ultrasonography identified multiple 
abnormalities including cystic hygroma, skin edema, ascites, and pleural effusion. Fetal MRI 
confirmed these findings and revealed profound hydrocephalus and cystic hygroma (Fig. 
1A,B). The fetus was motionless though there was a normal amount of amniotic fluid. 
Amniocentesis showed a normal 46, XX karyotype and microarray analysis was negative for 
aneuploidy. Whole genome chromosome SNP microarray analysis was normal as well. Alpha 
fetoprotein was elevated and viral PCRs for toxoplasmosis, parvovirus, cytomegalovirus, and 
HSV were all negative.  
Fetal echocardiogram showed normal fetal cardiac anatomy, function, and rhythm 
approximately 2 weeks prior to delivery. Fetal MRI showed a head circumference that 
appeared to be within the normal range but showed evidence of severe dilation of the lateral 
and third ventricles (Fig.1A). The pons, cerebellum, and spinal cord were thin. Both kidneys 
were below the 5th percenti le in size for gestational age. Contrary to the findings in MNMAT2-
deficient mice, there were no abnormalities in the bladder either grossly or microscopically 21. 
Both extremities remained in position and muscle planes were markedly diminished during 
fetal MRI. The fetus was delivered stillborn at approximately 27 weeks gestation. 
Fetal autopsy was performed at Cincinnati Children’s Hospital Medical Center. Gross 
inspection identified multiple congenital anomalies including: hydrops fetalis, cystic hygroma, 
bilateral hypoplastic lungs, hydrocephalus, hypoplastic cerebellum, severely reduced skeletal 
muscle mass or absence, flexion contractures of all extremities, micrognathia, cleft palate, and 














soft tissues. The musculature was very poorly developed and nearly absent in all extremities. 
The lungs were hypoplastic. The placenta was grossly hydropic with evidence of 
chorioamnionitis and very friable, spongy, dark red tissue with no focal areas of discoloration 
or evidence of infarcts. The umbilical cord had an eccentric insertion and the fetal membranes 
were not discolored. The spinal cord was thin and poorly developed throughout most of its 
length. A frozen section of the quadriceps muscle showed no recognizable skeletal muscle 
tissue and appeared to be composed essentially of immature fat tissue. There were no 
inflammatory cell infiltrates or evidence of degenerating or dysplastic skeletal muscle fibers. 
The brain was poorly developed and collapsed when the calvaria was opened along the suture 
lines. Evaluation of the brain was severely limited due to autolytic changes, however, sections 
showed very immature neural glial tissue and germinal matrix. Only one slide showed a few 
areas of recognizable cortex. 
 
Given this constellation of phenotypes, the cause of death in fetus 1 was determined to be 
hydrops fetalis with multiple congenital anomalies and fetal akinesia deformation sequence 
(FADS). It is unlikely the phenotypes were due to a congenital myopathy based on evaluation 
of the muscle biopsy taken at autopsy.  
 
Fetus 2. Fetus 2 was a second stillborn fetus of the same parents with an intervening healthy 
child (Fig.2A). The genetic analysis described below was used for prenatal counseling and 
fetus 2 was the product of prenatal genetic diagnosis/in vitro ferti lization (PGD/IVF) and was 
intended to be a carrier for NMNAT2 but developed severe hydrops at 16 weeks gestation as 














weeks gestation by Cesarean section and submitted for autopsy. Fetus 2 was diagnosed with 
hydrops fetalis with multiple fetal anomalies similar to fetus 1. Upon gross inspection, the fetus 
displayed hydropic changes including diffuse body wall and soft tissue edema with prominent 
nuchal fold (Fig. 1C). Markedly, there was apparent absence of skeletal muscle, especially that 
of the shoulder, extremities, pelvic girdle and absence of the psoas muscles, bi laterally (Fig. 
1C-E). Long bone formation appeared adequate in length but slender with reduced formation 
of the femoral neck and trochanters. Sections of the limbs showed adequately formed long 
bones with adequate bony trabecular marrow space with scant trilineage hematopoiesis. The 
surrounding tissue was composed of mainly fibroadipose tissue in an edematous background 
with very few skeletal muscle fibers (Fig. 1H, J). The nuclei of the skeletal muscle were plump 
and evenly distributed at the edges of the pink proteinaceous myocyte fibers (Fig. 1I).The 
carpal cartilages were fused.  Both the upper and lower limbs showed an abnormal absence of 
bundling of skeletal muscle fibers. The hands and feet had an unusual flattened appearance 
with severe contractures but adequate ray and digit bony formation (Fig. 1F,G).  
The heart was of normal weight with apparently normal myocardium, indicating the skeletal 
muscle was affected but the cardiac muscle was spared (Fig. 1K). The lungs were hypoplastic 
with normal lobar formation and no focal lesions or other abnormalities. No lesions were 
identified in the kidneys or bladder. The brain showed no significant gyration as expected for 
gestational age. 
The placenta showed variable villous immaturity with irregular contours and occasional 
trophoblastic inclusions. There was a vascular distribution of fetal thrombotic vasculopathy.  
The cause of death for fetus 2 was likely related to placental insufficiency with placental 














displayed many features of FADS including severely diminished muscle mass, pulmonary 
hypoplasia, joint contractures, and micrognathia.   
 
Exome Sequencing and Filtering 
Genetic analysis was performed upon birth of fetus 1. Karyotyping and whole genome SNP 
microarray were normal suggesting a monogenic disorder. Clinical whole exome sequencing of 
the trio (Father, Mother, and Fetus 1) (Fig. 2A) was performed at Ambry Genetics. Mean 
coverage was 77.0, 105.6, and 86.7 reads per base for the father, mother and fetus, 
respectively. Filtering was performed by Ambry as detailed in Table S1. Briefly, multiple 
inheritance models were tested resulting in 26 potential gene candidates (with 40 total coding 
alterations) over all models. Manual review was performed for sequencing artifacts, known 
polymorphisms, additional artifacts and benign alterations.  
NMNAT2 was identified as the remaining candidate in an autosomal recessive model with two 
unique alterations suggesting a compound heterozygous inheri tance pattern (Supp Table 1). 
By co-segregation analysis, both parents were found to be heterozygous for one of the two 
mutations identified in fetus 1. NMNAT2 was deemed clinically novel as no patients have been 
identified to date but there is significant phenotypic overlap between the patient’s phenotype 
with a mouse model of NMNAT2 deficiency and the mutations are predicted to be damaging by 
SIFT and Polyphen 21; 22. When fetus 2 was diagnosed with such similar features, NMNAT2 
was directly tested with Sanger sequencing and found to have the same compound 
















The maternally inherited variant was a single duplication of a cytosine at position 403 in exon 5 
resulting in a frameshift and premature stop after 44 amino acids in NMNAT2 (c.403dupC, 
p.Q135Pfs*44; confirmed by Sanger Sequencing; Fig. 2B,D). The paternally inherited variant 
was a missense mutation in exon 9 (c.695G>A, p.R232Q; confirmed by Sanger Sequencing; 
Fig. 2B) resulting in a coding change of arginine to glutamine at position 232 (R232Q). 
Conservation alignment shows R232 is highly conserved to D. melanogaster and has a 
PhastCons score of 1 (Fig. 2C). Multiple algorithms predict this to be damaging sequence 
change (e.g.., PolyPhen score of 0.97, SIFT 0.0 and is predicted to be “disease causing” by 
MutationTaster.  The family has one unaffected daughter who was identified to carry only one 
of the NMNAT2 mutations. This finding supports a recessive model in which both affected 
alleles must be inherited in order to develop FADS.  
Although the human NMNAT2 crystal structure has not been characterized, it is predicted that 
the enzyme activity domains share the same structure folds as those of human NMNAT1 and 
NMNAT3 38. The R232 equivalent residue is invariant in all three human NMNAT isoforms and 
NMNAT homologs across distant phyla (Fig. 2C), suggesting its importance in protein function. 
Given that the R232 residue is located within the conserved region, we examined the crystal 
structure of human NMNAT1 to evaluate the potential structure-function consequences of the 
R232Q mutation in NMNAT2 39 (Fig. 2E). The residue is located at the end of a β strand 
connecting the substrate binding domains for NMN and ATP , suggesting it is part of a 
conformational change upon binding the adenine group of ATP substrate or NAD/NaAD 39. It is 
predicted that the significant change in the side chain from arginine to glutamine will alter the 














the β strand and a helix, positioned at the surface of the protein that likely participates in the 
interface of protein-protein interaction (Fig. 2E).  
 
Both the NMNAT2R232Q and NMNAT2Q135Pfs*44 variants have reduced capacity to delay 
Wallerian Degeneration 
Overexpression of mouse or human (Flag-tagged) NMNAT2 is sufficient to delay Wallerian 
degeneration in cultured mouse superior cervical ganglion (SCG) neurons. This affords us a 
ready assay to measure the capacity of a variant to support axon survival 20; 40. We therefore 
assessed whether this property is affected by the NMNAT2R232Q or NMNAT2Q135Pfs*44 variants 
found in the affected patents. We introduced expression vectors for Flag-tagged wild-type or 
variant NMNAT2 into SCG neurons by microinjection. We used a concentration for which the 
resulting expression from the Flag-NMNAT2WT construct preserves integrity of the majority 
(~70%) of neurites of the injected neurons for at least 24 hours after transection. Under these 
conditions we found little or no preservation of cut neurites from SCG neurons injected with 
either Flag-NMNAT2R232Q or Flag-NMNAT2Q135Pfs*44 expression vectors (Fig. 3A, B). This lack 
of protection is comparable to the lack of protection seen after injection with empty vector or 
eGFP expression vector 20; 40. 
 
Importantly, even when using 2.5 times the vector concentration previously used in the 
Wallerian degeneration assays, expression of the NMNA T2Q135Pfs*44 variant was barely 
detectable above background by Flag immunostaining in injected neurons (Fig. 3C). In 
contrast, robust expression of Flag-NMNAT2R232Q was observed that closely matched that of 














any functionality, its inability to protect transected neurites in this assay could simply reflect 
very low levels of expression, whereas the failure of Flag-NMNAT2R232Q to protect must 
instead reflect either much more rapid loss of the mutant protein after injury relative to Flag-
NMNAT2WT, or a substantial loss of function. 
 
NMNAT2Q135Pfs*44 variant produces an unstable protein whereas NMNAT2R232Q variant is 
slightly more stable than wild-type NMNAT2 
To investigate whether the stability of either variant Flag-NMNAT2 protein is altered relative to 
Flag-NMNAT2WT, we assessed their relative rates of turnover in transfected HEK 293T cells 
after a protein synthesis block. Expression of the exogenous proteins was kept low to avoid 
saturation of the degradation machinery. Levels of Flag-NMNAT2WT and Flag-NMNAT2R232Q at 
the start of the protein synthesis block were comparable, whereas Flag-NMNAT2Q135Pfs*44 
levels were greatly reduced (Fig. 4A, B). Flag-NMNAT2Q135Pfs*44 migrates at the expected size 
for the truncated protein but, intriguingly, Flag-NMNAT2R232Q consistently migrates slightly 
slower than Flag-NMNAT2WT (Fig. 4A). To give a more representative comparison of turnover 
rate of the Flag-NMNAT2Q135Pfs*44 mutant we increased its expression to better match starting 
levels of the Flag-NMNAT2WT and Flag-NMNAT2R232Q (Fig. 4C). In broad agreement with 
previous analyses, we saw almost complete loss of Flag-NMNAT2WT within the 8 hour 
timeframe of these assays with only ~25% remaining at 2 hours (Fig. 4A,D) 20; 40. In 
comparison, Flag-NMNAT2Q135Pfs*44 was undetectable on blots even at 2 hours, even from the 
highest starting levels (Fig 4C), whereas significantly more Flag-NMNAT2R232Q  was detectable 
at both 2 and 4 hours (Fig. 4A,D). Notably however, Flag- NMNAT2R232Q was also almost 















These data indicate that Flag-NMNAT2Q135Pfs*44 is much less stable than Flag-NMNAT2WT 
whereas Flag-NMNAT2R232Q is modestly more stable. The reduced stability of Q135Pfs*44 
Flag-NMNAT2 could thus partly explain both its lower expression level in SCG neurons and 
transfected HEK cells and its greatly reduced capacity to protect injured axons (above), even 
in the unlikely event the severely truncated protein remains functional. In contrast, the slightly 
increased stability of Flag- NMNAT2R232Q instead suggests that its lack of axon-protective 
capacity is likely due to a loss of one or more other functional properties. 
 
NMNAT2R232Q variant displays impaired NAD synthase and chaperone functions 
Recombinant human NMNAT2WT, NMNAT2R232Q and NMNAT2Q135Pfs*44 were obtained as His-
tagged fusion proteins after bacterial expression and His-tag affinity chromatography. 
Typically, this yielded ~2 mg of relatively pure recombinant protein per 0.5 L of bacterial culture 
for both NMNAT2WT and NMNAT2R232Q (Fig. 5A and 5B). Notably, the purified NMNAT2R232Q 
was found to have NMNAT activity of just 0.51 ± 0.04 U/mg in these preparations compared to 
11.2 ± 0.23 U/mg for purified NMNAT2WT (Fig. 5C). In contrast, NMNAT2Q135Pfs*44 purifications 
yielded 0.1 mg or less of protein per 0.5 L of bacterial culture with a ~22 kDa His-tagged 
protein, corresponding in size to NMNAT2Q135Pfs*44, seemingly a relatively minor component of 
the preparations (Fig. 5A and 5B). This is consistent with low level expression of the truncated 
protein in bacteria, as in mammalian cells. While the highly heterogeneous NMNAT2Q135Pfs*44 
preparations did have detectable NMNAT activity, size-exclusion and ion exchange 
chromatography revealed that none of the activity was associated with the 22 kDa protein 














anti-His and anti-NMNAT2 antibodies (Fig. 5A and 5B), and thus likely to be His-tagged 
NMNAT2WT, probably accounts for the activity in these preparations. The origin of the full-
length protein in these clonal preparations remains unknown but correction of the frameshift 
mutation in the construct by ribosomal frameshifting or transcriptional slippage are possible 
explanations. Crucially, however, this effect is likely to be restricted to bacteria / prokaryotes as 
no detectable full-length NMNAT2WT is produced from a NMNAT2Q135Pfs*44 expression 
construct in HEK cells (Fig. 4C). Both NMNAT2R232Q and NMNAT2Q135Pfs*44 thus appear to 
have substantially reduced enzyme activity.  
 
The purity of NMNAT2R232Q preparations allowed us to perform further characterization that 
was not possible for NMNAT2Q135Pfs*44. NMNAT2R232Q was eluted as a monomer following size-
exclusion chromatography and was stable at -80 °C for months but was progressively 
inactivated after thawing, similar to wild type NMNAT2 34; 41. There was also a linear decline of 
NMNAT activity for NMNAT2R232Q at Mg2+ concentrations above 5 mM (Fig. 5D) so all 
subsequent assays were performed at MgCl2 concentrations only marginally exceeding the 
ATP concentration (see Methods) thus avoiding the large excess of free Mg2+ ions in solution 
usually employed for assaying NMNAT2WT 35; 36. Further assays revealed a relative thermal 
resistance and stability of NMNAT2R232Q which showed a markedly higher residual activity, at 
least relative to its lower baseline (Fig. 5C), than NMNAT2WT after 1 hour incubations at 
temperatures ranging from 25 °C to 47 °C  (Fig. 5E) and, at ~40 min, the activity half-life of 
NMNAT2R232Q at 37 °C was more than twice that of NMNAT2WT (Fig. 5F). Nevertheless, the 
optimum temperature for activity was the same for NMNAT2WT and NMNAT2R232Q (Fig. 5G). 














the enzyme: Kcat was found to be reduced by ~20-fold and the Km values for NMN and ATP 
were both increased ~10-fold (Table 2). These striking changes predict a ~200-fold reduced 
catalytic efficiency (Kcat/Km) of NMNAT2
R232Q compared to NMNAT2WT (Table 2). In fact, the 
loss of catalytic activity may even be greater in vivo where physiological concentrations of ATP 
(~1 mM) and NMN (5 µM) in brain predict a 500-fold or greater reduction compared to the wild 
type enzyme 42. 
 
Together, these data suggest that both NMNAT2R232Q and NMNAT2Q135Pfs*44 have a substantial 
loss of NMNAT activity. Although the R232Q mutation makes the enzyme slightly more 
resistant to heat denaturation in vitro, any increased stability is likely to be completely negated 
by the substantial detrimental effect it has on catalytic activity. In contrast, reduced 
expression/stability and impaired catalytic activity (largely predicted from the absence of key C-
terminal motifs resulting from truncation) likely combine to severely impair the activity of 
NMNAT2Q135Pfs*44. The presence of only NMNAT2R232Q and NMNAT2Q135Pfs*44 in neurons would 
thus be predicted to be highly limiting for NMN consumption and NAD+ biosynthesis in axons, 
thereby limiting survival. 
 
To characterize the chaperone function, we used an in-cell luciferase refolding assay to 
measure the ability of NMNAT isoforms to facilitate the refolding of unfolded luciferase after 
heat shock 43; 44 (Fig. 6). Chaperones may act as “holdases” to protect their client protein from 
unfolding, or as “foldases” to assist the folding to the native state 45; 46. The in-cell luciferase-
refolding assay allows the measurement of the luciferase unfolding after heat shock (red bars), 














NMNAT2WT and NMNAT2R232Q greatly protected luciferase from unfolding during heat shock, 
indicating strong “holdase” activity (Fig. 6, red bars). However, when “foldase” activity was 
analyzed, we found a remarkable loss of foldase activity specifically in NMNAT2R232Q 
expressing cells, while NMNAT2WT facilitated the refolding of luciferase after heat shock, 
comparable to heat shock protein 70 (Hsp70) and NMNAT3 (Fig. 6, green bars). Compared to 
NMNAT2WT and NMNATR232Q, NMNAT2Q135Pfs*44 did not exhibit either “holdase” or “foldase” 
activity, indicating a lack of stable or functional protein. 
 
Collectively, these biochemical and cellular analyses revealed two functional consequence of 
the NMNAT2 mutation p.R232Q: a significant loss of enzymatic activity and a complete loss of 
chaperone foldase activity. Considering the essential neuronal maintenance function of 
NMNAT220; 47; 48, disruption of both activities provides the molecular basis for compromised 
embryonic metabolism and neuronal development, contributing to FADS. 
 
DISCUSSION 
The critical role of NMNAT2 in promoting axon survival in mice has been well established 
using in vitro and in vivo models. Declining NMNAT2 levels have been associated with a 
variety of neurodegenerative diseases, including Alzheimer’s disease and other tauopathies 24; 
25; 29; 47; 49, but a direct role in human disease causation has not previously been demonstrated. 
Here we report two related fetuses that are both compound heterozygous for severe loss-of-
function NMNAT2 alleles. They both present with a FADS phenotype closely resembling that of 
homozygous null mice. Thus, for the first time, we present strong evidence that NMNAT2 loss 















We performed detailed molecular analyses of the NMNAT2 variants to support our claims. We 
first tested the ability of the variants to protect axons in a Wallerian Degeneration model. 
Consistent with previous reports, the NMNAT2WT construct was able to protect nearly 75% of 
axons from Wallerian Degeneration. However, both NMNAT2 variants were severely 
compromised in their ability to delay degeneration with 10% or less of neurites remaining intact 
24 hours post transection. These data argue both patient variants significantly impair NMNAT2 
function in PNS axons.  
 
We also performed in vitro experiments to specifically query enzymatic and chaperone 
functions for NMNAT2. We most conclusively demonstrated severe loss-of-function of the 
NMNAT2R232Q variant. The strong conservation of the R232 residue across evolutionarily 
distant NMNAT homologues suggested that the R232 residue is functionally relevant. The 
invariable R residue is at the end of a β strand connecting the substrate binding domains for 
NMN and ATP, therefore we predicted the R232Q mutation likely affects substrates and NAD+ 
binding. Indeed, we found the R232Q substitution substantially reduces affinity for both 
substrates and largely abolishes NMNAT activity of the variant protein.  Furthermore, R232 
forms the bend between the β strand and a helix and is positioned at the surface of the protein 
that likely participates in the interface of protein-protein interactions. The reduced refolding 
activity of NMNAT2R232Q is also thus consistent with reduced protein-protein interaction(s) with 
the cellular refolding machinery as a result of the missense mutation. Interestingly, 
NMNAT2R232Q also consistently shows retarded migration during electrophoresis. While the 














rigidity of the protein, the possibility that it might be the result of altered posttranslational 
modification also needs to be considered, especially in the context of the loss-of-function and 
increased stability of this variant.  
 
The relative instability of the NMNAT2Q135Pfs* variant protein largely precluded the same degree 
of functional assessment. However, this instability is probably sufficient on its own to explain 
the observed loss-of-function in our assays. Nevertheless, the fact that the frameshift mutation 
results in a truncated protein lacking its entire C-terminal half, including many residues that are 
critical for ATP binding, likely accounts for the apparent lack of NMNAT activity and makes it 
extremely likely that NMNAT2Q135Pfs*44 will also be defective for chaperone function. 
Interestingly, because we expressed NMNAT2Q135Pfs*44 from an intronless construct in our 
assays, its relative instability likely reflects an increased susceptibility of the truncated peptide 
to direct proteolytic cleavage. However, it remains possible that nonsense mediated decay of 
the aberrant mRNA could also further limit expression the FADS cases.  
 
Importantly, the FADS phenotype seen in the human patients shows broad overlap with that of 
MNMAT2-deficient mice, in particular the severely reduced skeletal muscle mass and akinesia, 
which are both likely due to failed peripheral innervation 21; 22. However, the human cases and 
the mouse model also show a number of notable differences. First,  viability is further reduced 
in humans; fetal patient demise occurs at around 27 weeks in gestation whereas MNMAT2-
deficient mice die perinatally. Second, at least one patient developed hydrocephalus in which 
the cortex was essentially spared. We do note Nmnat2 shows strong expression in the CNS 














Third, the bladder is consistently distended in the mouse model but we did not identify defects 
in the bladder of either patient. Crucially, these differences could all be related to significantly 
longer gestation and longer axons in humans than mice which likely allow for more severe 
neurodegeneration in humans in utero and an increased likelihood of fetal demise 51. In 
addition, some symptoms specific to the human cases, including cystic hygroma, ascites, and 
edema are likely to be a consequence of the fetal demise in utero. Interestingly, mice 
nullizygous for other FADS-associated genes, such as Dok7 and Musk 52; 53, have a phenotype 
remarkably similar to MNMAT2-deficient mice, providing additional support for a direct link 
between the NMNAT2 loss-of-function alleles in these cases and their FADS presentation. 
 
There is strong evidence in the li terature from several independent groups suggesting that 
NMNAT2 enzymatic activity is the key activity for preventing activation of Wallerian-like axon 
degeneration and that enzyme dead / chaperone competent mutants broadly fail to protect 
axons 13. At the moment it is not known whether NMNAT2 chaperone function also contributes 
to axon protection and the finding that blocking the Wallerian degeneration pathway by 
removal of SARM1 “fully” rescues axon defects and survival of mice lacking NMNAT2 
suggests that chaperone activity is dispensable for survival or overt health in mice, at least in 
the context of a relatively non-stressful home cage environment 26; 27.  However, as we found 
the R232Q variant affects both chaperone and NAD synthase functions of NMNAT2, we 
















We conclude that the compound heterozygous variant NMNAT2 alleles in the FADS cases 
described here encode proteins whose enzymatic and chaperone functions are both either 
directly or indirectly impaired and are a likely underlying cause of the disorder. As in MNMAT2-
deficient mice, we propose that defects in PNS axon outgrowth and/or survival primari ly lead to 
decreased innervation of the skeletal muscle in the fetuses resulting in severely reduced 
skeletal muscle mass. We argue NMNAT2 may be added to the growing list of genes involved 
in developing or maintaining PNS innervation that have been linked to FADS or FADS-
associated symptoms such as DOK7, MUSK, RAPSN, ADCY6, GPR126, ECEL1, GLDN, and 
PIEZO2 1. NMNAT2 mutations should be investigated in other cases with fetal hydrops, fetal 
akinesia, and widespread skeletal muscle deficiency. 
It will also be important to determine whether more modest NMNAT2 loss-of-function alleles 
are associated with other disorders. Interestingly, in the accompanying paper [Huppke et al; 
EXNR-19-319], another set of patients has been identified that are homozygous for a 
temperature-sensitive, partial loss-of-function NMNAT2 allele who develop a childhood-onset 
peripheral neuropathy phenotype. This raises the possibility of an NMNAT2 allelic series with 
mutations that have a less severe effect on NMNAT2 function leading to childhood or later-
onset neuropathies, rather than prenatal lethality, and/or preclinical phenotypes that 
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Figure 1. Gross phenotype and histology of affected fetuses. (A,B) Fetal MRI of Fetus II-1 
in which hydrocephalus is noted by asterisk and cystic hygroma by arrowhead. (C) Dorsal view 
of fetus II-3 with notable edema and lack of skeletal muscle in the extremities. (D) Fetus II-3 
displays malrotation of the gut with the appendix in the upper left quadrant. (E) Absence of the 
psoas muscles bilaterally is noted by the asterisks. (F,G) Fetus II-3 displays flattened hands 
with contractures of the elbow (F), and nearly complete absence of skeletal muscle of the leg 
(G). (H) Histology of the right radius and ulna shows reduced skeletal muscle fiber packing 
near the bone. (I) Histology of the interosseous muscles of the right hand show sparsely 
spaced muscle fibers with plump nuclei. (J) Histology of the hip joint shows fibrofatty tissue 
replacement of the musculature of the hip (K) Histology of the left ventricle shows normal 
architecture of the myocardium. 
  
 
Figure 2. Whole exome sequencing identifies compound heterozygous mutations in 
NMNAT2.  (A) Family pedigree. Stillborn infants are depicted as filled triangles with slashes 
(A). (B) Sanger sequencing of NMNAT2. (C) Conservation of arginine at aa232 in NMNAT2 
homologues across distant phyla. (D) Diagram of functional domains  of NMNAT2 with patient 
variant positions in red. (E) 3D structure model of NMNAT1. The conserved β strands and α 
helices important for enzymatic function are marked in yellow and cyan, respectively. The 
disordered region in NMNAT that contains the nuclear localization sequence is indicated by a 















Figure 3. NMNAT2R232Q and NMNAT2Q135Pfs*44 both have reduced capacity to maintain 
neurite survival. (A) Representative images (of n = 4 independent experiments) of cut 
neurites of SCG neurons co-injected with expression vectors for Flag-NMNAT2WT, or Flag-
NMNAT2R232Q, or NMNAT2Q135Pfs*44 (10 ng/µl) and DsRed (pDsRed2, 40 ng/µl). Neurites were 
cut 48 hours after injection when DsRed expression allows clear visualization of the distal 
neurites of the injected neurons. Images show transected neurites, just distal to the lesion, 
immediately after (0h) and 24 hours after cut. The lesion site is located the bottom edge of 
each field. Brightness and contrast have been adjusted for optimal visualization of neurites. (B) 
Quantification of neurite survival at 24 hours after cut for experiments described in panel A. 
The number of intact neurites with continuous DsRed fluorescence at 24 hours is shown as a 
percentage of intact neurites at 0h. Individual values and means ± SEM are plotted (individual 
values represent the average of two fields per separate culture). n.s. = not significant (p > 
0.05), *** p < 0.001, one-way ANOVA with Tukey’s multiple comparisons test. (C) Relative 
expression level of Flag-NMNAT2 variants in injected SCG neuron cell bodies. Representative 
fluorescent images of SCG neurons 24 hours after co-injection with expression vectors for 
Flag-NMNAT2WT, Flag-NMNAT2R232Q or Flag- NMNAT2Q135Pfs*44 and DsRed (each at 25 ng/µl). 
DsRed identifies injected neurons, Flag immunostaining shows expression of the Flag-
NMNAT2 proteins, and DAPI labels nuclei. Relative intensities (± SEM) of Flag 
immunostaining and DsRed signal are shown after transformation to the mean of levels in 
neurons injected with the Flag-NMNAT2WT construct. The data for WT, R232Q and 
Q135Pfs*44 were calculated from 47, 62 and 40 injected neurons (DsRed positive) of which 















Figure 4. Relative stabilities and activities of NMNAT2R232Q and NMNAT2Q135Pfs*44 in HEK 
293T cells. (A) Representative immunoblots (of n = 3) of extracts of HEK 293T cells co-
transfected with expression vectors for Flag-NMNAT2WT, Flag-NMNAT2R232Q or Flag-
NMNAT2Q135Pfs*44 and eGFP at the indicated times after addition of 10 µM emetine. Emetine 
was added 24 h after transfection. Extract from non-transfected cells is also shown (NT). Blots 
were probed with Flag, eGFP and -Tubulin antibodies. To avoid saturation of the protein 
degradation machinery that might artificially slow rates of turnover, expression of the Flag-
NMNAT2 proteins was kept relatively low by including empty vector as part of the transfection 
mix (see Materials and Methods). Co-transfected eGFP or endogenous -Tubulin (present in 
transfected and non-transfected cells) are both relatively stable proteins and were respectively 
used as a reference for Flag-NMNAT2 protein turnover (to control for transfection efficiency) 
and for loading. Arrows indicate the positions of bands corresponding to Flag-NMNAT2WT 
(black, ~34 kDa), Flag-NMNAT2R232Q (red, ~37 kDa), and Flag-NMNAT2Q135Pfs*44 (green, ~22 
kDa). The position of a faint non-specific band is also marked (*). (B) Relative steady-state 
Flag-NMNAT2 protein band intensities (0h, just before emetine addition) after normalization to 
co-transfected eGFP for blots described in panel A. Individual values (n = 4-5) and means 
±SEM are plotted. n.s. = not significant (p > 0.05), ** p < 0.01, one-way ANOVA with Tukey’s 
multiple comparisons test (only comparisons to Flag-NMNAT2WT. (C) Representative 
immunoblots (of n = 4) of extracts of HEK 293T cells, as in panel A, but transfected with a 
higher concentration of Flag-NMNAT2Q135Pfs*44 expression vector and with increased loading 
per lane to maximize Flag band intensity at the 0h time point so that its level at 0h is similar to 
that of Flag-NMNAT2WT in panel A. This allows for a more accurate comparison of turnover 














seen. (D) Relative turnover rates of Flag-NMNAT2 proteins after emetine addition. Flag-
NMNAT2 band intensities on blots described in panel A (Flag-NMNAT2WT and Flag-
NMNAT2R232Q) and panel C (Flag-NMNAT2Q135Pfs*44) were normalized to co-transfected eGFP 
and intensities at each time point after emetine addition were calculated as a proportion of the 
intensity of the 0h, untreated band. Means ± SEM (n = 4) are plotted. n.s. = not significant (p > 
0.05), ** p < 0.01 and *** p < 0.001, two-way ANOVA with Sidak’s multiple comparisons test for 
effects between variants. One-phase decay curves were fitted to the data sets for Flag-
NMNAT2WT and Flag-NMNAT2R232Q using non-linear regression. The R2 value and half-life (t½) 
are reported. No intensity values could be obtained for Flag-NMNAT2Q135Pfs*44 at any timepoint 
assessed after emetine addition precluding curve fitting and statistical analysis.   
 
 
Figure 5. Bacterial expression and in vitro characterization of the activity of 
recombinant NMNAT2R232Q and NMNAT2Q135Pfs*44. (A) Coomassie blue stained 12 % SDS 
polyacrylamide gel loaded with similar amounts (~3 g) of NMNAT2WT and each indicated 
recombinant NMNAT2 variant arising from His-tag affinity chromatography. (B) Immunoblots of 
~0.3 µg of the same protein samples as in A probed with anti-His and anti-NMNAT2 antibodies 
as indicated. As in HEK cells, bacterially-expressed NMNAT2R232Q migrates slower than 
NMNAT2WT and NMNAT2Q135Pfs*44, which lacks the epitope recognized by the NMNAT2 
antibody (raised against the C-terminus of the full-length protein), is expressed at a low level. 
The NMNAT2Q135Pfs*44 preparation contains a ~34 kDa protein recognized by both anti-His and 
anti-NMNAT2 antibodies that is likely to be His-tagged NMNAT2WT (red boxes). (C) NMNAT 














concentrations of substrates. The less pure NMNAT2Q135Pfs*44 preparation is omitted despite 
some activity found since it was not associated with the His-tagged 22 kDa truncated protein 
arising from the frame shift mutation (see text). (D) Magnesium-dependent rates of NMNAT 
activity referred to 1 mM MgCl2 (arbitrary 100 % value). (E) Enzyme stability after 1 hour 
treatment at different temperatures. Treated enzyme solutions were then assayed at 37 °C. 
Relative rates are expressed as percentages of the untreated enzyme kept at 4 °C (100 % not 
shown). (f) Enzyme stability at 37 °C as function of time. Rates are relative to time zero. (g) 
Optimum temperature after heating of whole assay mixtures at the indicated temperatures. 
Relative rates are expressed as percentages of the maximum observed (42 °C for both 
enzymes). All data presented are the mean ± SEM from n = 3 independent measures. T test p 
values vs corresponding WT are marked by (*) p < 0.015 or by (**) p < 0.005 (Two Sample t 
Test, unequal variances). 
 
 
Figure 6. NMNAT2R232Q and NMNAT2Q135Pfs*44 have reduced chaperone activities. HEK 
293T cells were co-transfected with luciferase and one of the following plasmids: DsRed2 
vector (control), Hsp70, NMNAT3, NMNAT2WT, NMNAT2R232Q, and Nmnat2Q135Pfs*44. At 48 hrs 
after transfection, protein synthesis was inhibited, and cells were subjected to heat shock at 42 
°C for 45 mins, and then recovered at 37 °C for 3 hours.  Quantification of luciferase activity 
measured without heat shock (blue bars), after heat shock (red bards), and after recovery 
(green bars). Luciferase activity in each group was normalized to no heat shock (set to 1). All 































Table 1. Clinical Features of fetuses II-1 and II-3. 
 
Measurement II-1 II-3 
 Reference 
 (24 weeks) 
Weight 810 g 282.2 g 586 ± 74g 
Crown to rump length 23 cm 23.5 cm 21 ± 1.4 cm 
Head circumference 25.5 cm 17.4 cm 21.8 ± 1.4 cm 
Inner canthal distance 2c m 1.9 cm 1.5 ± 0.17 cm 
Outer canthal distance 5c m 3.4 cm 4.21 ± 0.41 cm 
Foot length 4.5 cm 3 cm 4.4 ± 0.2 cm 
Lung weight 3.6 g 1.7 g 15.8 ± 5.3g 
Heart weight 3.4 g 0.9 g 4.4 ± 0.9g 
Brain weight 100 g 45 g 81.7 ± 14.8g 

























Placenta area 18x17 cm N/A 
 Fetal hydrops + + 
 Cystic hygroma + + 
 Flexion contractures + + 
 Lung hypoplasia + + 
 Hydrocephalus + Unknown 
 Hypoplastic cerebellum + Unknown 
 Muscle atrophy + + 
 Micrognathia + + 
 Cleft palate + + 
 Hydropic placenta + + 















Table 2. Kinetic parameters of human NMNAT2 WT and R232Q. 
Enzyme Substrate Km (M) Kcat (s
-1) Kcat/Km (s
-1M-1) 
NMNAT2WT ATP 159.6 + 28.6 6.84 + 3.21 0.429 * 105  
NMN 22.3 + 8.13 6.84 + 3.21 3.070 * 105 
NMNAT2R232Q ATP 1820.9 + 121.1 0.31 + 0.03 0.002 * 105 
NMN 178.5 + 10.8 0.31 + 0.03 0.017 * 105 
 

















 Two stillborn fetuses with FADS carry compound heterozygous mutations in NMNAT2 
 NMNAT2 synthesizes NAD+ and acts as a molecular chaperone in neurons 
 Both patient mutations impair both NAD+ biosynthesis and chaperone functions 
 Both patient mutations fail to delay Wallerian Degeneration in cultured neurons 
 Mutations in NMNAT2 impair Wallerian Degeneration and lead to human disease  
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